Sorafenib Tablets 200mg
SORALIEVA 200MG (Sorafenib Tablets 200mg) is a targeted anticancer medicine used in the treatment of specific types of liver cancer, kidney cancer, and thyroid cancer. It contains Sorafenib Tosylate, a multikinase inhibitor that helps slow the growth and spread of cancer cells by blocking certain proteins and signaling pathways involved in tumor development and blood vessel formation.
Cancer cells require a constant supply of nutrients and oxygen to grow and spread. Sorafenib works by targeting multiple kinases involved in cancer cell proliferation and angiogenesis (the formation of new blood vessels that feed tumors). By blocking these pathways, SORALIEVA 200MG helps reduce tumor growth and may slow disease progression in eligible patients.
Unlike conventional chemotherapy, Sorafenib is a targeted therapy designed to interfere with specific molecular mechanisms that support cancer growth. This approach makes it an important treatment option in modern oncology, especially for patients with advanced or metastatic cancers.
SORALIEVA 200MG is commonly prescribed for:
• Hepatocellular Carcinoma (HCC) – Liver Cancer
• Advanced Renal Cell Carcinoma (RCC) – Kidney Cancer
• Differentiated Thyroid Carcinoma (DTC)
• Advanced or Metastatic Solid Tumors
• Long-Term Targeted Cancer Therapy Programs
The medicine is often recommended when surgery or other treatment options are not suitable, or when cancer has progressed despite previous therapies.
Manufactured under stringent pharmaceutical quality standards, SORALIEVA 200MG is designed to provide reliable therapeutic performance and consistent quality. It should only be used under the supervision of qualified oncologists or healthcare professionals experienced in cancer treatment.
Patients undergoing treatment with Sorafenib may require regular blood tests, liver function monitoring, blood pressure assessments, and imaging studies to evaluate treatment effectiveness and manage potential side effects.
Due to its effectiveness in advanced cancer management, SORALIEVA 200MG has become an important component of modern targeted oncology treatment protocols worldwide.
View Details
Lenvatinib Capsules 10mg
LENVALIEVA 10 MG (Lenvatinib Capsules 10 mg) is a prescription targeted anticancer medicine containing Lenvatinib 10 mg, an advanced multi-kinase inhibitor used for the treatment of several types of cancer. It is commonly prescribed for patients with thyroid cancer, liver cancer, kidney cancer, and endometrial cancer, helping to slow tumor growth, delay disease progression, and improve treatment outcomes.
Lenvatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs). It works by blocking specific proteins involved in tumor growth and blood vessel formation. Cancer cells require a continuous blood supply to receive oxygen and nutrients needed for growth. LENVALIEVA 10 MG helps prevent the formation of new blood vessels that feed tumors, thereby limiting cancer progression.
Unlike conventional chemotherapy, which attacks rapidly dividing cells throughout the body, Lenvatinib specifically targets pathways involved in cancer growth and angiogenesis (blood vessel formation). This targeted approach has made it an important component of modern oncology treatment strategies.
LENVALIEVA 10 MG is commonly prescribed for:
Differentiated Thyroid Cancer (DTC)
Radioactive Iodine-Refractory Thyroid Cancer
Hepatocellular Carcinoma (Liver Cancer)
Advanced Renal Cell Carcinoma (Kidney Cancer)
Advanced Endometrial Cancer
Metastatic Solid Tumors (Selected Cases)
Targeted Oncology Treatment Programs
Long-Term Cancer Management
The medicine may be used alone or in combination with other anticancer therapies depending on the patient's diagnosis, disease stage, and treatment goals.
Lenvatinib has become a valuable treatment option because it targets multiple pathways involved in cancer progression, helping improve disease control in patients with advanced cancers.
Manufactured according to stringent pharmaceutical quality standards, LENVALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenvatinib therapy require routine medical monitoring, including blood pressure assessments, liver function tests, kidney function evaluations, thyroid monitoring, and regular clinical examinations.
Due to its targeted mechanism and broad clinical applications, LENVALIEVA 10 MG plays an important role in modern cancer care worldwide.
View Details
Lenvatinib Capsules 4mg
LENVALIEVA 4 mg contains Lenvatinib, an oral multi-targeted tyrosine kinase inhibitor (TKI). It inhibits multiple receptors involved in tumor growth and angiogenesis, including VEGFR 1–3, FGFR 1–4, PDGFR-α, RET, and KIT, thereby suppressing tumor vascularization and proliferation.
View Details
